Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | PDE4A | P27815 | 3/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etamiphyllin SCHEMBL355304 | 0.91 | ADORA2B (0.67) | ADORA2BLMNAMAPTPDE4APDE4B | |
| Etamiphyllin SCHEMBL1651150 | 0.88 | ADORA2B (0.63) | ADORA2BLMNAMAPTPDE4APDE4B | |
| Etofylline SCHEMBL149271 | 0.83 | ADORA2B (1.00) | ADORA2BLMNAMAPTPDE4APDE4B | |
| SCHEMBL683551 | 0.83 | ADORA2B (0.70) | ADORA2BLMNAMAPTPDE4APDE4B | |
| Bamifylline SCHEMBL28086377 | 0.82 | TSHR (0.53) | ADORA2BLMNAMAPTSMN1; SMN2ADORA1 | |
| SCHEMBL683897 | 0.82 | ADORA2B (0.71) | ADORA2BLMNAMAPTPDE4APDE4B | |
| SCHEMBL11381846 | 0.81 | ADORA2B (0.64) | ADORA2BLMNAMAPTSMN1; SMN2POLB | |
| Dimethazan SCHEMBL49056 | 0.81 | PDE4A (0.73) | ADORA2BLMNAMAPTPDE4APDE4B | |
| SCHEMBL9293406 | 0.81 | ADORA2B (0.83) | ADORA2BLMNAMAPTPDE4APDE4B | |
| SCHEMBL16120984 | 0.80 | ADORA2B (0.81) | ADORA2BLMNAMAPTSMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040013609-A1 | For identification of substances for treatment or prevention of insufficient longitudinal growth of eye(hypermetropia) or excessive longitudinal growth of eye(myopia); involves measurement of effect on retinal pigment epithelium | TRIER KLAUS (DK) | 2004-01-22 | — | — | US | claimed |
| US-6710051-B1 | SUBSTANCES IS A XANTHINE AND IS ADMINISTERED IN A DOSAGE OF 7.5-750 MG 1-4 TIMES DAILY TO TREAT MYOPIA | KLAUS TRIER APS (DK) | 2004-03-23 | — | — | US | disclosed |
| US-20040013609-A1 | For identification of substances for treatment or prevention of insufficient longitudinal growth of eye(hypermetropia) or excessive longitudinal growth of eye(myopia); involves measurement of effect on retinal pigment epithelium | TRIER KLAUS (DK) | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040013609-A1 | For identification of substances for treatment or prevention of insufficient longitudinal growth of eye(hypermetropia) or excessive longitudinal growth of eye(myopia); involves measurement of effect on retinal pigment epithelium | RYR1, ATP2A2, ATP2A1 | ADORA2B 826/4885LMNA 824/4885MAPT 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.